Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
New antimicrobial agents and novel combination therapies are needed to treat serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to daptomycin and vancomycin. The purpose of this study was to evaluate the combination of ceftaroline plus daptomycin or vancomycin in an in vitro pharmacokinetic/pharmacodynamic model. Simulations of ceftaroline-fosamil at 600 mg per kg of body weight every 8 h (q8h) (maximum free-drug concentration in serum [ fC max ], 15.2 mg/liter; half-life [ t 1/2 ], 2.3 h), daptomycin at 10 mg/kg/day ( f C max , 11.3 mg/liter; t 1/2 , 8 h), vancomycin at 2 g q12h ( fC max , 30 mg/liter; t 1/2 , 6 h), ceftaroline plus daptomycin, and ceftaroline plus vancomycin were evaluated against a clinical, isogenic MRSA strain pair: D592 (daptomycin susceptible and heterogeneous vancomycin intermediate) and D712 (daptomycin nonsusceptible and vancomycin intermediate) in a one-compartment in vitro pharmacokinetic/pharmacodynamic model over 96 h. Therapeutic enhancement of combinations was defined as ≥2 log 10 CFU/ml reduction over the most active single agent. The effect of ceftaroline on the membrane charge, cell wall thickness, susceptibility to killing by the human cathelicidin LL37, and daptomycin binding were evaluated. Therapeutic enhancement was observed with daptomycin plus ceftaroline in both strains and vancomycin plus ceftaroline against D592. Ceftaroline exposure enhanced daptomycin-induced depolarization (81.7% versus 72.3%; P = 0.03) and killing by cathelicidin LL37 ( P < 0.01) and reduced cell wall thickness ( P < 0.001). Fluorescence-labeled daptomycin was bound over 7-fold more in ceftaroline-exposed cells. Whole-genome sequencing and mutation analysis of these strains indicated that change in daptomycin susceptibility is related to an fmtC ( mprF ) mutation. The combination of daptomycin plus ceftaroline appears to be potent, with rapid and sustained bactericidal activity against both daptomycin-susceptible and -nonsusceptible strains of MRSA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., Philippakis, A. A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,456
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Self-citationWhole genome sequencing of meticillin-resistant Staphylococcus aureus
Kuroda, M., Ohta, T., Uchiyama, I., Baba, T., Yuzawa, H., Kobayashi, I., Cui, L., Oguchi, A., Aoki, K.-I., Nagai, Y., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04403-2 · Cited by 1,961
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir034 · Cited by 1,599
Stampy: A statistical algorithm for sensitive and fast mapping of Illumina sequence reads
Lunter, G., & Goodson, M. (2011) · Genome Research · doi:10.1101/gr.111120.110 · Cited by 1,016
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Peschel, A., Jack, R. W., Otto, M., Collins, L. V., Staubitz, P., Nicholson, G., Kalbacher, H., Nieuwenhuizen, W. F., Jung, G., Tarkowski, A., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.9.1067 · Cited by 786
Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus
Silverman, J. A., Perlmutter, N. G., & Shapiro, H. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2538-2544.2003 · Cited by 656
Research works printed but not linked: 1
- 33. Sakoulas G, Rose WE. 2011. Effect of beta-lactam (BL) exposure in vitro on daptomycin (DAP) activity and cell wall thickness in MRSA, poster E-1332. Abstr. 51st Annu. Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL [Google Scholar]
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citationThe Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent
Ridyard, K. E., & Overhage, J. (2021) · Antibiotics · doi:10.3390/antibiotics10060650 · Cited by 270
“DAP exhibits antibacterial effects against heterogeneous VAN-intermediate S. aureus (hVISA), VISA [208], MRSA and vancomycin-resistant enterococci (VRE) [207].”
BackgroundInfluentialA Current Perspective on Daptomycin for the Clinical Microbiologist
Humphries, R. M., Pollett, S., & Sakoulas, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-13 · Cited by 240
Self-citationWhole-Genome Analyses of Enterococcus faecium Isolates with Diverse Daptomycin MICs
Diaz, L., Tran, T. T., Munita, J. M., Miller, W. R., Rincon, S., Carvajal, L. P., Wollam, A., Reyes, J., Panesso, D., Rojas, N. L., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02686-14 · Cited by 139
Singh, M., Thakur, V., Kumar, V., Raj, M., Gupta, S., Devi, N., Upadhyay, S. K., Macho, M., Banerjee, A., Ewe, D., et al. (2022) · Molecules · doi:10.3390/molecules27175587 · Cited by 151
Large Retrospective Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy
Casapao, A. M., Davis, S. L., Barr, V. O., Klinker, K. P., Goff, D. A., Barber, K. E., Kaye, K. S., Mynatt, R. P., Molloy, L. M., Pogue, J. M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02371-13 · Cited by 108
“This may have also accounted for some use of ceftaroline in our patient population (4–6), as ceftaroline has demonstrated in vitro activity against these resistant pathogens (29, 30).”
BackgroundSelf-citationCombination Antibiotic Treatment of Serious Methicillin-Resistant Staphylococcus aureus Infections
van Hal, S. J., Tong, S. Y. C., & Davis, J. S. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1396906 · Cited by 118
Can β-Lactam Antibiotics Be Resurrected to Combat MRSA?
Foster, T. J. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.06.005 · Cited by 117
Moise, P. A., Amodio-Groton, M. I., Rashid, M., Lamp, K. C., Hoffman-Roberts, H., Sakoulas, G., Yoon, M., Schweitzer, S., & Rastogi, A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02192-12 · Cited by 97
Self-citationMcCreary, E. K., Kullar, R., Geriak, M., Zasowski, E. J., Rizvi, K., Schulz, L. T., Ouellette, K., Vasina, L., Haddad, F. A., Rybak, M. J., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz538 · Cited by 98
“Additionally, ceftaroline has been shown to enhance DAP binding and cell membrane depolarization, resulting in rapid, sustained bactericidal activity against MRSA [19, 20].”
BackgroundSelf-citationBarber, K. E., Ireland, C. E., Bukavyn, N., & Rybak, M. J. (2014) · Infectious Diseases and Therapy · doi:10.1007/s40121-014-0023-0 · Cited by 90
Self-citationDaptomycin: The role of high-dose and combination therapy for Gram-positive infections
Gould, I. M., Miró, J. M., & Rybak, M. J. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.05.005 · Cited by 93
Self-citationBerti, A. D., Sakoulas, G., Nizet, V., Tewhey, R., & Rose, W. E. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00594-13 · Cited by 87
Self-citationZasowski, E. J., Trinh, T. D., Claeys, K. C., Casapao, A. M., Sabagha, N., Lagnf, A. M., Klinker, K. P., Davis, S. L., & Rybak, M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02015-16 · Cited by 82
“This interaction is likely mediated by enhanced cationic HDP cell membrane binding through increased membrane negativity and is analogous to the mechanism of synergy observed between daptomycin and ceftaroline (29, 30).”
BackgroundResultSelf-citationDhand, A., & Sakoulas, G. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.09.005 · Cited by 80
Self-citationTreatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond
Holmes, N. E., Tong, S. Y. C., Davis, J. S., & van Hal, S. J. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1397040 · Cited by 94
Agents Targeting the Bacterial Cell Wall as Tools to Combat Gram-Positive Pathogens
Zhydzetski, A., Głowacka-Grzyb, Z., Bukowski, M., Żądło, T., Bonar, E., & Władyka, B. (2024) · Molecules · doi:10.3390/molecules29174065 · Cited by 87
“Ceftaroline possesses a side chain mimicking peptidoglycan structure, which can activate PBP2a and allow binding to the active site [18] and its inhibition.”
BackgroundTong, S. Y. C., Nelson, J., Paterson, D. L., Fowler, V. G., Howden, B. P., Cheng, A. C., Chatfield, M. D., Lipman, J., van Hal, S., O'Sullivan, M. V. N., et al. (2016) · Trials · doi:10.1186/s13063-016-1295-3 · Cited by 77
“β-Lactams have been shown to enhance binding of daptomycin to the bacterial cell wall [49].”
BackgroundContemporary Management of Staphylococcus aureus Bacteremia—Controversies in Clinical Practice
Minter, D. J., Appa, A. A., Chambers, H. F. “., & Doernberg, S. B. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad500 · Cited by 86
“In vitro studies suggest synergistic activity between high-dose daptomycin and either ceftaroline or ASPs [70].”
BackgroundWerth, B. J., Vidaillac, C., Murray, K. P., Newton, K. L., Sakoulas, G., Nonejuie, P., Pogliano, J., & Rybak, M. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02354-12 · Cited by 69
“Data are currently limited regarding potential synergy between vancomycin and ceftaroline (12).”
BackgroundSelf-citationRose, W. E., Fantl, M., Geriak, M., Nizet, V., & Sakoulas, G. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab452 · Cited by 74
“Like other β-lactams, ceftaroline enhances daptomycin cell membrane binding [24].”
Self-citationWhen sepsis persists: a review of MRSA bacteraemia salvage therapy
Kullar, R., Sakoulas, G., Deresinski, S. C., & van Hal, S. J. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv368 · Cited by 76
Self-citationOrtwine, J. K., Werth, B. J., Sakoulas, G., & Rybak, M. J. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2013.10.002 · Cited by 70
“1) and an increase in the negative charge of the cell surface (Berti et al., 2012; Dhand et al., 2011; Werth et al., 2012).”
BackgroundMethodSelf-citationBerti, A. D., Theisen, E., Sauer, J., Nonejuie, P., Olson, J., Pogliano, J., Sakoulas, G., Nizet, V., Proctor, R. A., & Rose, W. E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02071-15 · Cited by 70
Self-citationBarber, K. E., Werth, B. J., Ireland, C. E., Stone, N. E., Nonejuie, P., Sakoulas, G., Pogliano, J., & Rybak, M. J. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku236 · Cited by 65
Self-citationWerth, B. J., Steed, M. E., Kaatz, G. W., & Rybak, M. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02308-12 · Cited by 61
Self-citationGudiol, F., Aguado, J. M., Almirante, B., Bouza, E., Cercenado, E., Domínguez, M. Á., Gasch, O., Lora-Tamayo, J., Miró, J. M., Palomar, M., et al. (2015) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2015.03.015 · Cited by 78
Snyder, A. H., Werth, B. J., Barber, K. E., Sakoulas, G., & Rybak, M. J. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku113 · Cited by 61
Self-citationSmith, J. R., Barber, K. E., Raut, A., & Rybak, M. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00053-15 · Cited by 62
“faecium, and Staphylococcus aureus (24, 25, 50, 51).”
Self-citationAntibiotic tolerance and the alternative lifestyles of Staphylococcus aureus
Bui, L. M. G., Conlon, B. P., & Kidd, S. P. (2017) · Essays in Biochemistry · doi:10.1042/ebc20160061 · Cited by 63
Barber, K. E., Smith, J. R., Ireland, C. E., Boles, B. R., Rose, W. E., & Rybak, M. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00386-15 · Cited by 57
“However, potent in vitro synergy has been identified with the combination of -lactam antibiotics plus either daptomycin or vancomycin (10, 11).”
BackgroundSelf-citationWerth, B. J., Barber, K. E., Ireland, C. E., & Rybak, M. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00088-14 · Cited by 56
“The combination of CPT plus DAP is known to enhance DAP binding by 7-fold and to increase the activity of human cationic antimicrobial peptides produced by the immune system (13).”
BackgroundSelf-citationGlucose Augments Killing Efficiency of Daptomycin Challenged Staphylococcus aureus Persisters
Prax, M., Mechler, L., Weidenmaier, C., & Bertram, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150907 · Cited by 55
“aureus by DAP is enhanced upon combination with other antibiotics [36,37] or D-cycloserine [38].”
BackgroundTran, N. N., & Rybak, M. J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00157-18 · Cited by 54
Self-citationBarber, K. E., Werth, B. J., McRoberts, J. P., & Rybak, M. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02764-13 · Cited by 52
“Ceftaroline appears to lower cell surface charge (17), and this change in net surface charge may potentially decrease the attraction of biofilm-producing organisms to prosthetic material.”
BackgroundSelf-citationWerth, B. J., Ashford, N. K., Penewit, K. M., Waalkes, A., Holmes, E. A., Ross, D. H., Shen, T., Hines, K. M., Salipante, S. J., & Xu, L. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.08.025 · Cited by 47
Self-citationJohnson, T. M., Molina, K. C., Miller, M. A., Kiser, T. H., Huang, M., & Mueller, S. W. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106310 · Cited by 51
Barber, K. E., Rybak, M. J., & Sakoulas, G. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku322 · Cited by 49
Self-citationHines, K. M., Shen, T., Ashford, N. K., Waalkes, A., Penewit, K. M., Holmes, E. A., McLean, K., Salipante, S. J., Werth, B. J., & Xu, L. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz562 · Cited by 44
Self-citationWhatʼs new in the treatment of serious MRSA infection?
Holmes, N. E., & Howden, B. P. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000101 · Cited by 52
“Heteroresistance to ceftaroline has been reported in laboratory isolates of MRSA, hVISA, VISA, DNS and LNS S. aureus [92].”
BackgroundInfluentialCurrent and prospective treatments for multidrug-resistant gram-positive infections
Rybak, J. M., Barber, K. E., & Rybak, M. J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.820276 · Cited by 46
“Daptomycin plus ceftaroline was evaluated versus ceftaroline plus vancomycin in an in vitro PK/PK model against an isogenic strain pair of hVISA and DNS VISA [93].”
MethodSelf-citationBarber, K. E., Werth, B. J., & Rybak, M. J. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku378 · Cited by 45
Self-citationGritsenko, D., Fedorenko, M., Ruhe, J., & Altshuler, J. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.12.005 · Cited by 45
Ceftaroline Fosamil: A Brief Clinical Review
Shirley, D.-A. T., Heil, E. L., & Johnson, J. K. (2013) · Infectious Diseases and Therapy · doi:10.1007/s40121-013-0010-x · Cited by 48
Snyder, A. D. H., Werth, B. J., Nonejuie, P., McRoberts, J. P., Pogliano, J., Sakoulas, G., Yim, J., Singh, N. B., & Rybak, M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00687-16 · Cited by 41
“Daptomycin binding was assessed by fluorescence microscopy in the presence and absence of fosfomycin and G-6-P as previously described (24).”
MethodSelf-citationMultifunctional Pharmaceutical Effects of the Antibiotic Daptomycin
Ye, Y., Xia, Z., Zhang, D., Sheng, Z., Zhang, P., Zhu, H., Xu, N., & Liang, S. (2019) · BioMed Research International · doi:10.1155/2019/8609218 · Cited by 42
“DAP+Ceftaroline MRSA Syn Enhance the binding of DAP In vitro [61, 62]”
BackgroundPharmacotherapeutic options for treating Staphylococcus aureus bacteremia
Gudiol, C., Cuervo, G., Shaw, E., Pujol, M., & Carratalà, J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1403585 · Cited by 63
Thivierge, K., Cotton, S., Schaefer, D. A., Riggs, M. W., To, J., Lund, M. E., Robinson, M. W., Dalton, J. P., & Donnelly, S. (2013) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002307 · Cited by 41
Fields, R. N., & Roy, H. (2018) · RNA Biology · doi:10.1080/15476286.2017.1356980 · Cited by 38
“bacteria that are increasingly resistant to current drugs, new antimicrobials and/or drug combinations must be identified to find effective treatments of managing infections.(108,109) In the last”
BackgroundClaeys, K. C., Smith, J. R., Casapao, A. M., Mynatt, R. P., Avery, L. M., Shroff, A., Yamamura, D. L. R., Davis, S. L., & Rybak, M. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04141-14 · Cited by 37
Self-citationCortes-Penfield, N. W., Oliver, N. T., Hunter, A. S., & Rodriguez‐Barradas, M. C. (2018) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2018.1448110 · Cited by 34
“Beta-lactams with affinity for penicillin-binding protein (PBP) 1 enhance the antimicrobial activity of daptomycin; this effect appears to be mediated by improved daptomycin binding to the bacterial cell membrane [2].”
BackgroundPeriprosthetic Joint Infections: Clinical and Bench Research
Legout, L., & Senneville, É. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/549091 · Cited by 32
“The treatment failure rate was 19.7% in methicillinsusceptible Staphylococcus aureus (MSSA-) infected patients versus 29.4% in MRSA-infected patients (𝑃 = 0.38).”
BackgroundInfluentialSynergistic bactericidal effects of phage-enhanced antibiotic therapy against MRSA biofilms
Coyne, A. J. K., Stamper, K. C., Bleick, C. R., Kebriaei, R., Lehman, S. M., & Rybak, M. J. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03212-23 · Cited by 39
“DAP concentrations were measured by a validated high-performance liquid chromatography (HPLC) assay and CPT concentrations were determined by bioassay as previously described (53, 54).”
MethodSelf-citationJahanbakhsh, S., Singh, N. B., Yim, J., Kebriaei, R., Smith, J. R., Lev, K. L., Tran, T. T., Rose, W. E., Arias, C. A., & Rybak, M. J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02074-19 · Cited by 35
Self-citationSmith, J. R., Yim, J., Raut, A., & Rybak, M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03006-15 · Cited by 35
Self-citationAlosaimy, S., Sabagha, N., Lagnf, A. M., Zasowski, E. J., Morrisette, T., Jorgensen, S. C. J., Trinh, T. D., Mynatt, R. P., & Rybak, M. J. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00292-8 · Cited by 35
Self-citationMolina, K. C., Morrisette, T., Miller, M. A., Huang, V., & Fish, D. N. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00468-20 · Cited by 32
Morrisette, T., Alosaimy, S., Abdul‐Mutakabbir, J. C., Kebriaei, R., & Rybak, M. J. (2020) · Antibiotics · doi:10.3390/antibiotics9110762 · Cited by 33
“The authors described that CPT reduced cell wall thickness, enhanced DAP-induced depolarization and enhanced killing by human cathelicidin LL37 [46].”
BackgroundMethodInfluentialSelf-citationKebriaei, R., Rice, S., Stamper, K. C., & Rybak, M. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01743-18 · Cited by 28
Self-citationMa, Z., Lasek‐Nesselquist, E., Lu, J., Schneider, R. F., Shah, R., Oliva, G., Pata, J. D., McDonough, K. A., Pai, M. P., Rose, W. E., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198366 · Cited by 28
Self-citationCombination of Vancomycin or Daptomycin and Beta‐lactam Antibiotics: A Meta‐analysis
Kale-Pradhan, P. B., Giuliano, C. A., Jongekrijg, A., & Rybak, M. J. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2437 · Cited by 27
Self-citationNichols, C., Wardlow, L. C., Coe, K. E., & Sobhanie, M. M. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab327 · Cited by 26
Gatin, L., Saleh‐Mghir, A., Tasse, J., Ghout, I., Laurent, F. J., & Crémieux, A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03600-14 · Cited by 25
“Indeed, clinical observations (16) and in vitro data (17) suggest that adding CPT to DAP could restore DAP susceptibility to DAP-resistant strains (16).”
BackgroundYim, J., Smith, J. R., Singh, N. B., Rice, S., Stamper, K. C., de la Mària, C. G., Bayer, A. S., Mishra, N. N., Miró, J. M., Tran, T. T., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx130 · Cited by 25
Self-citationDilworth, T. J., Leonard, S. N., Vilay, A. M., & Mercier, R.-C. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.06.027 · Cited by 26
“Nafcillin and ceftaroline have been shown to alter S aureus cell wall surface charge, which allowed for enhanced daptomycin binding against daptomycin-nonsusceptible S aureus.(36,37) MRSA cell wall surface charge should not influence VAN activity, but TZP’s affinity for PBP1 in S aureus may be important when consideri…”
BackgroundStryjewski, M. E., Jones, R. N., & Corey, G. R. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.11.016 · Cited by 23
“In vitro data have shown that ceftaroline increases membrane binding and enhances daptomycin activity against daptomycin non-susceptible, vancomycin-intermediate S. aureus (Werth et al., 2013).”
BackgroundJiang, S., Zhuang, H., Zhu, F., Xiang, W. D., Zhang, J., Sun, L., Ji, S., Wang, H., Wu, D., Zhao, F., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01295-21 · Cited by 23
“increasing the frequency of septation and cell wall abnormalities, boosting the immune system, and reducing virulence (11, 29, 30).”
BackgroundAprile, I. G., Bordieri, C., Gilardi, A., Milazzo, M. L., Russo, G., Santis, F. D., Frusciante, R., Iannaccone, E., Erra, C., Ricci, E., et al. (2013) · PubMed · Cited by 31
Ceftaroline for the treatment of methicillin-resistantStaphylococcus aureusbacteremia
White, B. P., Barber, K. E., & Stover, K. R. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160006 · Cited by 25
Smith, J. R., Yim, J., Rice, S., Stamper, K. C., Kebriaei, R., & Rybak, M. J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00101-18 · Cited by 21
Self-citationCoyne, A. J. K., Stamper, K. C., Ghali, A. E., Kebriaei, R., Biswas, B., Wilson, M., Deschenes, M. V., Tran, T. T., Arias, C. A., & Rybak, M. J. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00340-23 · Cited by 25
Self-citationChambers, H. F. “., Basuino, L., Hamilton, S. M., Choo, E. J., & Moise, P. A. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00589-16 · Cited by 20
“The combination of daptomycin and a beta-lactam enhances killing against daptomycin-susceptible and daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA) (1–3), increases daptomycin binding to the bacterial cell membrane (2, 4, 5), and prevents the development of daptomycin resistance (3, 6, 7).”
BackgroundLi, B., Kang, W. C. M., Liu, H., Wang, Y., Yu, C., Zhu, X., Dou, J., Cai, H., & Zhou, C. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0769-x · Cited by 20
“Antibiotics such as blactamantibiotics and daptomycin can destroy the cell walls of bacteria, which allows AMPs to bind more easily to the exposed membrane and thus promotes a bactericidal effect (Werth et al. 2013).”
Smith, J. R., Arya, A., Yim, J., Barber, K. E., Hallesy, J. A., Singh, N. B., & Rybak, M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01666-15 · Cited by 19
“Ceftaroline, in particular, has demonstrated the ability to enhance daptomycin activity against daptomycin-nonsusceptible strains of MRSA (6, 10, 11, 13, 26).”
BackgroundSelf-citationCraig, W. A., & Andes, D. R. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00021-7 · Cited by 23
Ceftaroline: Systematic Review of Clinical Uses and Emerging Drug Resistance
Abate, G., Wang, G. C., & Frisby, J. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221082326 · Cited by 19
Patel, D., Brown, M. L., Edwards, S., Oster, R. A., & Stripling, J. T. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106735 · Cited by 20
Martins, F. S., Martins, J. E. S., Severino, P. B., Annaert, P., & Sy, S. K. B. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15731 · Cited by 18
Huang, C., Chen, I., & Lin, L. (2022) · Antibiotics · doi:10.3390/antibiotics11081104 · Cited by 17
Yi, Y.-H., Wang, J., Yin, W., & Xu, W. (2021) · Microbial Drug Resistance · doi:10.1089/mdr.2020.0350 · Cited by 19
“33,34 However, the findings that DAP plus ceftaroline improved survival within 30 days for MRSA bacteremia are preliminary and include only a small number of patients.”
Lounsbury, N., Reeber, M. G., Mina, G., & Chbib, C. (2019) · Antibiotics · doi:10.3390/antibiotics8010030 · Cited by 21
“Further research of the in vitro synergy with daptomycin and ceftaroline combination was found to be caused by multiple mechanisms: a decrease in bacterial cell-wall thickness, an increase in daptomycin binding and an increase in daptomycin-induced depolarization [24,31,32].”
BackgroundBavaro, D. F., Belati, A., Bussini, L., Cento, V., Diella, L., Gatti, M., Saracino, A., Pea, F., Viale, P., & Bartoletti, M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2299377 · Cited by 19
“Importantly, studies showed that fifth-generation cephalosporins could be a valuable monotherapy for bacteremic patients with similar clinical cure and mortality rate if compared to vancomycin or daptomycin [147,170–175], considered the backbone of MRSA-BSI treatment from decades.”
BackgroundResultDaptomycin synergistic properties from in vitro and in vivo studies: a systematic review
Antonello, R. M., Canetti, D., & Riccardi, N. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac346 · Cited by 17
Use of Daptomycin to Manage Severe MRSA Infections in Humans
Fiore, M., Alfieri, A., Fiore, D., Iuliano, P., Spatola, F. G., Limone, A., Pezone, I., & Leone, S. (2025) · Antibiotics · doi:10.3390/antibiotics14060617 · Cited by 18
“Werth et al. evaluated the DAP–CPT combination in a pharmacokinetic/pharmacodynamic model simulating endocardial vegetations and observed significantly enhanced bacterial killing compared to that observed with either agent alone [67].”
InfluentialVancomycin plus ceftaroline for persistent methicillin‐resistant Staphylococcus aureus bacteremia
Kufel, W. D., Parsels, K. A., Blaine, B. E., Steele, J. M., Mahapatra, R., Paolino, K. M., & Thomas, S. J. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2741 · Cited by 14
Henson, K. E. R., Yim, J., Smith, J. R., Sakoulas, G., & Rybak, M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01564-16 · Cited by 14
“It has been previously demonstrated that exposure to CPT increases DAP binding to the cell membrane, resulting in enhanced DAP activity (5).”
BackgroundSelf-citationMorrisette, T., Lagnf, A. M., Alosaimy, S., & Rybak, M. J. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03941-5 · Cited by 14
Self-citationA rapid single-phase extraction for polar staphylococcal lipids
Bimpeh, K., & Hines, K. M. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-04758-9 · Cited by 14
Abdul‐Mutakabbir, J. C., Kebriaei, R., Stamper, K. C., Sheikh, Z., Maassen, P. T., Lev, K. L., & Rybak, M. J. (2020) · Antibiotics · doi:10.3390/antibiotics9100696 · Cited by 14
“Several studies have shown improved activity with the use of a cell-wall active agent, more specifically CFZ or CPT in addition to DAP through both 96 h PK/PD modelling and TKA [14,19].”
BackgroundSelf-citationTsai, C.-E., Yang, C., Chuang, Y., Wang, J., Sheng, W., Chen, Y., & Chang, S. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.05.057 · Cited by 14
Zampino, R., Gallo, R., Salemme, A., Marrazzo, T., Iossa, D., Karruli, A., Andini, R., Esitini, D., Moretto, S. M., Gregorio, F. D., et al. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106883 · Cited by 12
Божкова, С. А., Муртузалиевич, Т. Р., Краснова, М. В., & Rukina, A. N. (2013) · Traumatology and Orthopedics of Russia · doi:10.21823/2311-2905-2013--4-5-15 · Cited by 12
Pee, C. J. E., Pader, V., Ledger, E. V. K., & Edwards, A. M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02105-18 · Cited by 12
Zapata, B., Alvarez, D. N., Farah, S., García-de-la-Maria, C., Miró, J. M., Sakoulas, G., Bayer, A. S., & Mishra, N. N. (2018) · Current Microbiology · doi:10.1007/s00284-018-1491-3 · Cited by 12
Self-citationOno, D., Yamaguchi, T., Hamada, M., Sonoda, S., Sato, A., Aoki, K., Kajiwara, C., Kimura, S., Fujisaki, M., Hiroyuki, T., et al. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2018.12.007 · Cited by 11
ElFeky, D. S., Awad, A. R., Elshobaky, M. A., & Elawady, B. A. (2019) · Surgical Infections · doi:10.1089/sur.2019.229 · Cited by 11
Lew, C. I., Mishra, N. N., Bayer, A. S., & Rose, W. E. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00356-21 · Cited by 12
“, nafcillin and ceftaroline) to DAP treatment has proven effective in many well-characterized cases of recalcitrant MRSA infections caused by DAP-R strains (14, 16, 30).”
BackgroundSelf-citationCoyne, A. J. K., Bleick, C. R., Stamper, K. C., Kebriaei, R., Bayer, A. S., Lehman, S. M., & Rybak, M. J. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01388-23 · Cited by 12
“CPT concentrations were determined by bioassay using Bacillus subtilis ATCC 6633 (36).”
MethodSelf-citationBactericidal and Bacteriostatic Antibiotics
Patil, S. M., & Patel, P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.99546 · Cited by 15
Metadata
- Authors
- Werth, B. J., Sakoulas, G., Rose, W. E., Pogliano, J., Tewhey, R., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- New York Medical College (US)
- University of Wisconsin–Madison (US)
- University of California San Diego (US)
- Scripps Research Institute (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2013-01
- Volume
- 57
- Issue
- 1
- Pages
- 66-73
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3535972
- OpenAlex
- W2138194474
- Semantic Scholar
- 39f34553cf23e3b9cdab27a62a417c2840f7a855
- Cited by
- 134
- References
- 40
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 11 · 2020: 13 · 2019: 8 · 2018: 8 · 2017: 7 · 2016: 11 · 2015: 12 · 2014: 19 · 2013: 12
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Update notices
- correction (2013-02-14)
- Open access
- green
- europepmc.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (R21A1092055-01)
- National Center for Research Resources (UL1RR025774)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- ceftaroline, daptomycin, vancomycin-intermediate Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, combination antibiotic therapy, pharmacokinetic-pharmacodynamic modeling, membrane depolarization, cell wall thickness, ceftaroline fosamil
- MeSH terms
- Ceftaroline, Anti-Bacterial Agents, Bacterial Proteins, Cell Membrane, Cell Wall, Cephalosporins, Drug Combinations, Drug Synergism, Fluorescent Dyes, Models, Biological, Mutation, Vancomycin, Colony Count, Microbial, Genome, Bacterial, Daptomycin, Aminoacyltransferases, Vancomycin Resistance, Antimicrobial Cationic Peptides, Microbial Viability, Cathelicidins, Methicillin-Resistant Staphylococcus aureus, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.